BASF Pharma Solutions’ excipient Soluplus has been accepted into the US Food and Drug Administration’s (FDA) Pilot Program for the Review of Innovation and Modernisation of Excipients (PRIME).
The program seeks to reduce the risk and burden for pharmaceutical companies wishing to utilise novel excipients for modern drug development challenges as well as to provide a pathway for excipient manufacturers like BASF to obtain FDA review of their novel excipients prior to use in an FDA-approved drug.
The Soluplus branded excipient has now moved into the next stage of the extensive evaluation process, and the FDA will share the results at the conclusion of this process.
As the need for novel excipients has never been greater, we are optimistic that a successful pilot program will lead to a formal novel excipient review program in the near future
“With our long history of developing novel excipients, it is especially rewarding that BASF is selected to participate in this pilot program,” said Jeff DeAlmeida, Senior Vice President, BASF Pharma Solutions. “We chose to submit this particular excipient for the FDA’s consideration as it can be used in the development of a wide range of vital medicines.”
The Soluplus branded excipient (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer) was specifically designed to improve the solubility and oral bioavailability of poorly soluble active pharmaceutical ingredients, which has been an ever-increasing challenge to the industry. “The review of novel excipients is a critical step in driving innovation in new materials to meet the global health challenges of today and the future,” said Dominik Odenbach, Director of Global Quality, Regulatory Compliance and External Affairs, BASF Pharma Solutions. Soluplus® is particularly suitable as a matrix polymer in hot melt extrusion, a key enabling technology utilised in numerous modern medicines.
“We would like to thank the FDA for introducing the novel excipient Pilot Program. IPEC-Americas, the IQ Pharma Consortium, and the USP all recognise the need for excipient innovation and the challenges for the adoption of novel excipients in drug development. The collaborative efforts among these groups have supported and advocated for this initiative. As the need for novel excipients has never been greater, we are optimistic that a successful pilot program will lead to a formal novel excipient review program in the near future,” said Nigel Langley, Global Technology Director at BASF and a Chair of IPEC-Americas.
